Diabetes drugs Pharmacological effects Pharmacokinetics Synthesis method Safety Drug interactions
ChemicalBook > CAS DataBase List > Dapagliflozin

Dapagliflozin

Diabetes drugs Pharmacological effects Pharmacokinetics Synthesis method Safety Drug interactions
Product Name
Dapagliflozin
CAS No.
461432-26-8
Chemical Name
Dapagliflozin
Synonyms
Dapagliflozin Propanediol Monohydrate;Dapagliflozin propanediol;Farxiga;DAPAGLIFLOZIN BASE;Dapagliflozi;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol;D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-;2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol;(2S,4R,5R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol;CS-179
CBNumber
CB91011730
Molecular Formula
C21H25ClO6
Formula Weight
408.88
MOL File
461432-26-8.mol
More
Less

Dapagliflozin Property

Melting point:
55-58°C
Boiling point:
609.0±55.0 °C(Predicted)
Density 
1.349
storage temp. 
2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
13.23±0.70(Predicted)
form 
Solid
color 
White to Pale Yellow
Stability:
Hygroscopic
InChIKey
JVHXJTBJCFBINQ-JNTNYNDRNA-N
SMILES
O[C@@H]1[C@H]([C@H](O)[C@@H](CO)O[C@H]1C1C=CC(Cl)=C(CC2C=CC(OCC)=CC=2)C=1)O |&1:1,2,3,5,9,r|
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

H318Causes serious eye damage

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P310Immediately call a POISON CENTER or doctor/physician.

P314Get medical advice/attention if you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
11574
Product name
Dapagliflozin
Purity
≥98%
Packaging
1mg
Price
$33
Updated
2024/03/01
Cayman Chemical
Product number
11574
Product name
Dapagliflozin
Purity
≥98%
Packaging
5mg
Price
$90
Updated
2024/03/01
Cayman Chemical
Product number
11574
Product name
Dapagliflozin
Purity
≥98%
Packaging
10mg
Price
$164
Updated
2024/03/01
Cayman Chemical
Product number
11574
Product name
Dapagliflozin
Purity
≥98%
Packaging
50mg
Price
$367
Updated
2024/03/01
TRC
Product number
D185370
Product name
Dapagliflozin
Packaging
10mg
Price
$120
Updated
2021/12/16
More
Less

Dapagliflozin Chemical Properties,Usage,Production

Diabetes drugs

Dapagliflozin (ForxigaTM) is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. It is also the first approved SGLT2 inhibitor for the treatment of type II diabetes, being an important option in the treatment of diabetes, and is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.
Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.
The post-marketing trial requested by the FDA includes a cardiovascular outcome trial for assessing the cardiovascular risk for high-risk patients after treatment with dapagliflozin at baseline and a study to assess the risk of bladder cancer in recruited patients. Another study will assess the bladder tumor-promoting effect of this drug on rodent animals. Two studies will assess the pharmacokinetics, efficacy and safety of dapagliflozin in pediatric patients; a set of strengthened pharmacovigilance program will monitor liver abnormalities and pregnancy outcome reports in patients receiving daglitazone. Dapagliflozin will be marketed under the tradename Farxiga by Haoeyou Pharmacy.
The above information is edited by Andy of chemicalbook.

Pharmacological effects

Dapagliflozin works through inhibiting sodium-glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the bloodstream. This allows extra glucose to be excreted through the urine, improving glycemic control without increasing insulin secretion. The use of this drug requires patients with normal renal function while patients of moderate to severe renal insufficiency should be disabled to use this drug. Single application of this product or combination with metformin, pioglitazone, glimepiride, insulin and other drugs can significantly reduce the HbA1c and fasting blood glucose of patients suffering type II diabetes. The frequency of the adverse reaction was similar to placebo with low risk of hypoglycemia, being able to reduce body weight.
The efficacy of dapagliflozin is comparable with the dipeptidyl peptidase inhibitors, and several new hypoglycemic drugs, and can also mildly lower the blood pressure and body weight. The drug has 5mg and 10mg two tablets to choose from, can be either used alone or together with insulin, including other diabetes drugs.

Pharmacokinetics

In healthy subjects, dapagliflozin was rapidly absorbed after oral administration with a peak time Tmax being 1 to 2 hours, a protein binding rate of 91%, an oral bioavailability of about 78% and a plasma terminal half-life of 12.9 hours. After oral administration, the drug is mainly metabolized by the uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9) into the inactive metabolite in the liver with the smaller part being metabolized by the P450 enzyme and of no inhibitory or inducing effect on the P450 enzyme. Drug prototypes and related metabolites were excreted through urine (75%) and faeces (21%). Compare simultaneous administration of this product with high-fat food and with the fasting administration, Tmax can be extended by 1-fold, but the absorption did not affect the degree, so can be administrated together with the food.
The pharmacokinetics of daglitazone was significantly affected by renal function. Diabetic patients with mild, moderate or severe renal insufficiency are merged to be subject to oral administration of 20 mg • d-1 daglitazone for 7 days. The mean systemic exposure amount, compared with patients with normal renal function, is respectively 32%, 60% and 87% higher. For patients with normal renal function, mild insufficiency, moderate insufficiency and severe insufficiency, the urinary glucose excretion amount in 24 hours of steady state was 85, 52, 18 and 11g, successively.
Kasichayanula et al have studied the pharmacokinetic effects of liver dysfunction on daglitazone. The patients with mild, moderate and severe hepatic insufficiency having a single oral dose of 10 mg of daglitazone, the Cmax of each group was 12% lower, 12% higher and 40% higher than that with normal liver function, respectively. The AUC of each group was significantly higher than that of normal liver function by 3%, 36% and 67%.
Therefore, it is not recommended to apply daglitazone to patients of moderate and severe renal dysfunction. Severe liver dysfunction patients need to reduce the use of dose.

Synthesis method

5-bromo-2-chlorobenzoic acid is subject to acylating chlorination, and has Friedel-Crafts reaction with phenylethyl ether for reduction of its carbonyl group, generating 5-bromo-2-chloro-4'-ethoxydiphenyl methane, further subjecting to condensation with 2, 3, 4, 6-tetra-O-trimethylsilyl-D-glucopyranosanoic acid-1,5-lactone. The anomeric carbon hydroxyl group is subject to etherification and deprotection to give 2-chloro-5-(1-methoxy-D-glucopyranose-I-yl)-4'-ethoxydiphenylmethane, and then use Et3SiH/BF3 • OEt2 for reduction to remove methoxy, followed by acetic anhydride esterification and hydrolysis to give hypoglycemic agents daglitazone with the overall yield of about 40%.

Fig.1 shows the chemical reaction route of synthesizing dapagliflozin.

Safety

Daglitazone has excellent tolerance and safety with the incidence of adverse events associated with 10 mg • d-1 daglitazone being similar to that of placebo. Common adverse events included hypoglycemia, polyuria, back pain, genital infections, urinary tract infections, dyslipidemia and hematocrit (HCT) increase. The overall risk of hypoglycemia is low, and the incidence of hypoglycemia is associated with other basic hypoglycemic agents. The incidence of hypoglycemia was higher in patients subjecting to joint treatment between daglitazone and sulfonylureas or insulin compared with placebo. Therefore, when this product is used in combination with insulin or insulin secretagogue, you may need to adjust the dose of the latter one.

Drug interactions

This product is mainly metabolized in the liver by UGT1A9 metabolism, being the P-glycoprotein substrate. Study confirmed that the pharmacokinetics of daglitazone was not affected by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, and simvastatin, valsartan, warfarin, and digoxin. The serum concentrations of the above-mentioned drugs are also not clinically significantly affected by daglitazone. Rifampicin can reduce the exposure amount of daglitazone by 22% while mefenamic acid can increase the body exposure amount by 51%, but have no clinically significant effect on 24 h urine glucose excretion.

Description

The Australian Therapeutic Goods Administration (TGA) and the European Commission approved dapagliflozin in October and November 2012, respectively, as an adjunct to diet and exercise for the treatment of type 2 diabetes. Dapagliflozin is a potentially attractive therapy due to its glucosesensitive and insulin-independent mechanism of action. It is a first-in-class selective SGLT2 inhibitor (IC50=1.1 nM; selectivity vs. SGLT1 >1000) that lowers the renal threshold for reabsorption of glucose, allowing excess glucose to be eliminated via the kidneys. In normal rats, administration of dapagliflozin promotes dose-dependent excretion of up to 1900 mg of glucose over a 24 h period, with amaximal effect at 3 mg/kg. In a ratmodel of diabetes, pretreatment with the pancreatic toxin streptozotocin results in hyperglycemia that is reduced 55% by administration of a single 0.1 mg/kg dose of dapagliflozin compared with vehicle. Aryl O-glucoside SGLT2 inhibitors were early entrants into the clinic, but the aryl C-glucoside linkage found in dapagliflozin confers resistance to glucosidase-mediated metabolism leading to improved clinical utility relative to aryl O-glucosides. The modified carbohydrate–aglycone linkage required concomitant adjustment from an ortho- to a meta-substituted arylglucoside to achieve potent SGLT2 inhibition. Dapagliflozin was synthesized in several steps via reaction of an aryllithium with per-silylated gluconolactone to form the key C-glucoside linkage. An alpha-selective reduction of the resultant anomeric glycoside gave the desired beta-Carylglucoside. The main circulating (inactive) metabolite is the result of 3-O-glucuronidation of the glucosylmoiety. Of the minority metabolites, the main oxidative species result from O-dealkylation of the ethoxy-group and hydroxylation of the biarylmethane moiety.

Description

Inhibiting renal glucose reabsorbtion through the sodium-glucose cotransporter (SGLT) offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes. While the majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is predominantly expressed in the kidney S1 segment of the proximal tubule, SGLT1 reabsorbs glucose in the distal S3 segment of the renal proximal tubule as well as from the small intestine. Dapagliflozin is a first generation, selective SGLT inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM; EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM). After single oral doses ranging from 0.1 to 1.0 mg/kg, dapagliflozin increases urinary glucose excretion in both normal and diabetic rats, improves glucose tolerance in normal rats, and reduces hyperglycemia in Zucker diabetic fatty rats. Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg dapagliflozin, fasting and fed glucose levels have been shown to be significantly lowered as a result of increased glucose utilization accompanied by reduced glucose production.

Chemical Properties

White Solid

Originator

Bristol-Myers Squibb (United States)

Uses

A sodium-glucose transporter 2 inhibitor.

Uses

therapeutic for diabetes I or II, and hyperglycemia

Definition

ChEBI: A C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic ontrol, along with diet and exercise, in adults with type 2 diabetes.

brand name

Forxiga

Clinical Use

Selective and reversible inhibitor of sodium-glucose co-transporter 2:
Treatment of type 2 diabetes

in vitro

ec50 values of 1.1 nm for hsglt2 and 1.4 μm for hsglt1 determined for dapagliflozin corresponded to 1200-fold selectivity for sglt2 as compared with phlorizin’s 10-fold selectivity. dapagliflozin inhibitory potencies against rat sglt (rsglt)2 and hsglt2 were comparable, but the selectivity of dapagliflozin for rsglt2 versus rsglt1 decreased to 200-fold [1].

in vivo

in vivo, dapagliflozin acutely induced renal glucose excretion in diabetic and normal rats, improved glucose tolerance in normal rats, as well as reduced hyperglycemia in zucker diabetic fatty rats after single oral doses ranging between 0.1 and 1.0 mg/kg [2].

target

hSGLT2

Metabolism

Dapagliflozin is extensively metabolised, primarily to dapagliflozin 3-O-glucuronide, which is an inactive metabolite. The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP-mediated metabolism was a minor clearance pathway in humans. About 75% of the dose is excreted in the urine and 21% in the faeces.

References

[1] meng w, ellsworth ba, nirschl aa, mccann pj, patel m, girotra rn, wu g, sher pm, morrison ep, biller sa, zahler r, deshpande pp, pullockaran a, hagan dl, morgan n, taylor jr, obermeier mt, humphreys wg, khanna a, discenza l, robertson jg, wang a, han s, wetterau jr, janovitz eb, flint op, whaley jm, washburn wn. discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (sglt2) inhibitor for the treatment of type 2 diabetes. j med chem. 2008 mar 13;51(5):1145-9.
[2] han s, hagan dl, taylor jr, xin l, meng w, biller sa, wetterau jr, washburn wn, whaley jm. dapagliflozin, a selective sglt2 inhibitor, improves glucose homeostasis in normal and diabetic rats. diabetes. 2008 jun;57(6):1723-9.
[3] bailey cj, iqbal n, t'joen c, list jf. dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. diabetes obes metab. 2012 oct;14(10):951-9.

Dapagliflozin Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Dapagliflozin Suppliers

Bangladesh 1 Brazil 1 Canada 4 China 537 France 3 Germany 5 Greece 1 India 107 Indonesia 1 Italy 1 Pakistan 1 Poland 2 Singapore 1 South Korea 1 Spain 2 Switzerland 1 The Netherlands 2 United Kingdom 4 United States 46 Global 721
CHENGHUI PHARMACEUTICAL GROUP LTD
Tel
0531-58897070 15254140813
Fax
0531-58897046
Email
market@jnchsd.com
Country
China
ProdList
214
Advantage
58
Cangzhou Enke Pharma-tech Co., Ltd.
Tel
0317-5296180 15533709196
Fax
0317-5106596
Email
sale@enkepharma.com
Country
China
ProdList
1898
Advantage
55
Sichuan Mingjian Pharmaceutical Chemical Co., Ltd.
Tel
15281098982
Email
sales@mjpharma.cn
Country
China
ProdList
57
Advantage
58
Anhui Cheer-Our Medical technology Co.,Ltd
Tel
0551-63535381 13485700777
Email
gaylen@cheer-our.com
Country
China
ProdList
93
Advantage
58
Jinan Chenghui Shuangda biological Co., LTD
Tel
0531-58897003 15550412551
Fax
0531-58897003
Email
market@jnchsd.com
Country
China
ProdList
212
Advantage
62
Jinan Duowei Innovation Biotechnology Co., Ltd
Tel
0531-58595315 13864187945
Email
415834789@qq.com
Country
China
ProdList
93
Advantage
58
Hubei Yuanmeng Biotechnology Co., Ltd
Tel
027-68897569 18120462897
Fax
027-68897569
Email
fiona@yuanmengbio.com
Country
China
ProdList
2075
Advantage
58
Jinan Sanyuan Chemical Co. LTD
Tel
0531-58585914 13335164090
Fax
0531-58585914
Email
1660423085@qq.com
Country
China
ProdList
412
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chemvon Biotechnology Co., Ltd
Tel
021-50790412
Fax
+86-21-50790419
Email
info@chemvon.com
Country
China
ProdList
371
Advantage
57
ZHIWE CHEMTECH CO LTD
Tel
021-20221225 13917446399
Fax
QQ:115820162
Email
sales@zhiwe.net
Country
China
ProdList
608
Advantage
61
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
Shijiazhuang Sdyano Fine Chemical Co., Ltd.
Tel
0311-89250318 031166536426
Fax
4000311741
Email
master@sjzsdyn.com
Country
China
ProdList
2963
Advantage
65
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9976
Advantage
60
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9499
Advantage
66
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
chenyj@titansci.com
Country
China
ProdList
14103
Advantage
59
Anhui Lianchuang Biological Medicine Co.,Ltd
Tel
0551-68779238 18056025720
Email
sales3@lcywhx.com
Country
China
ProdList
159
Advantage
57
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
19172
Advantage
64
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
13327700685
Fax
+86-25-58744115
Email
sales@vcarepharmatech.com
Country
China
ProdList
310
Advantage
61
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
Fax
86-0571-85151182
Country
China
ProdList
5691
Advantage
66
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8838
Advantage
52
Shanghai Kuanghao Chemistry Technology Co., Ltd.
Tel
13130049594 13130049594
Fax
021-37285512
Email
83219210@qq.com
Country
China
ProdList
95
Advantage
57
Tongchuang Pharma(Suzhou). Co., Ltd.
Tel
0512-63263366 18912765016
Fax
0512-6326 3366
Email
tongtf110@sina.com
Country
China
ProdList
972
Advantage
62
Shanghai Sphchem Co., Ltd.
Tel
21-21-56491756 13512199871
Fax
021-5649-1756
Email
sales@panhongchem.com
Country
China
ProdList
4000
Advantage
55
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9658
Advantage
60
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Country
China
ProdList
4727
Advantage
58
Changzhou Joyous Chemical Co., Ltd.
Tel
0519-85607258
Fax
0519-85607278
Email
sales@joyouschem.com
Country
China
ProdList
294
Advantage
60
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-4000505016 13380397412
Fax
0755 28094224
Email
3001272453@qq.com
Country
China
ProdList
5047
Advantage
50
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Fax
+86 755 28094224
Country
China
ProdList
4496
Advantage
50
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9865
Advantage
52
Nanjing JinruiJiuAn Biotechnology Co., Ltd.
Tel
025-58196018 800028039
Fax
025-83453306
Email
sales@fartop.net
Country
China
ProdList
2229
Advantage
55
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
Nanjing Norris-Pharm Technology Co., Ltd
Tel
13901585132
Fax
+86-25-52131256
Email
799750417@qq.com
Country
China
ProdList
8878
Advantage
55
China Kouting Group Limited
Tel
+86 (21) 5811-6473 5811-6475
Fax
+86 (21) 6129-4103
Email
sales@koutingchina.com
Country
China
ProdList
496
Advantage
60
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-400-6206333 18521732826
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25003
Advantage
65
The future of Shanghai Industrial Co., Ltd.
Tel
021-61552785
Fax
021-55660885
Email
sales@shshiji.com
Country
China
ProdList
9545
Advantage
55
Acesys Pharmatech
Tel
18860950986
Email
tangmanman@zenjipharma.com
Country
China
ProdList
1733
Advantage
55
China Nobel Chem Co., Limited
Tel
+86(0)21 60484900
Fax
+86(0)21 60484900
Country
China
ProdList
764
Advantage
50
Shanghai MOF Chemical Tech Limited
Tel
13661494087 18964793018
Fax
86-021-51821718 QQ：2427604606
Email
sales@mof-chemicals.com
Country
China
ProdList
293
Advantage
55
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4428
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
ShangHai YingYi Chemical Technology Co., Ltd.
Tel
86-21-50700185 13764109623
Fax
86-21-50700185
Email
sale@inyelchem.com
Country
China
ProdList
178
Advantage
55
GIHI CHEMICALS CO.,LTD
Tel
0086-571-86217390
Fax
0086-571-86217391
Email
Sales@gihichem.com
Country
China
ProdList
860
Advantage
58
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
Country
China
ProdList
3466
Advantage
58
Shanghai JONLN Reagent Co., Ltd.
Tel
400-0066400 13621662912
Fax
021-55660885
Email
422131432@qq.com
Country
China
ProdList
9978
Advantage
55
More
Less

View Lastest Price from Dapagliflozin manufacturers

Sinoway Industrial co., ltd.
Product
Dapagliflozin 461432-26-8
Price
US $0.00-0.00/Kg/Bag
Min. Order
1Kg/Bag
Purity
99% min / GMP application / PMDA / DMF
Supply Ability
20 tons
Release date
2024-06-27
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Dapagliflozin 461432-26-8
Price
US $0.00/Kg/Bag
Min. Order
100g
Purity
99%min
Supply Ability
20kg
Release date
2021-08-05
Nanjing Fred Technology Co., Ltd
Product
Dapagliflozin 461432-26-8
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%，single impurity＜0.1
Supply Ability
1 ton
Release date
2024-01-04

461432-26-8, DapagliflozinRelated Search:

Pioglitazone hydrochloride D-Glucitol, 1,5-dideoxy-1,5-epithio-1-C-[5-[(4-ethoxyphenyl)Methyl]-2-Methoxy-4-Methylphenyl]-, (1S)- Tofogliflozin LX-4211 Ipragliflozin PF-04971729 Selumetinib MK-2206 2HCl Dasatinib IKK Inhibitor III, BMS-345541 AZD-9291 Dapagliflozin iMpurity Canagliflozin Empagliflozin Liraglutide Saxagliptin dimebolin Ramelteon

  • DAPAGLIFLOZIN
  • (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
  • Dapagliflozin propanediol
  • BMS-512148-05
  • Dapagliflozin S1548 Selleck
  • DAPAGLIFLOZIN BASE
  • Daglican
  • Dapagliflozi
  • CS-179
  • Dagliel
  • 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
  • Bms 512148
  • D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-
  • Dapagliflozin(BMS-512148)
  • (2S,4R,5R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol
  • 1-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-deoxy-beta-D-glucopyranose (1S)-1,5-Anhydro-1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol
  • (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxyMethyltetrahydro-2H-pyran-3,4,5-triol
  • 1-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-deoxy-beta-D-glucopyranose
  • BMS5121458
  • Dag coluMn net
  • Dapagliflozin Propanediol Monohydrate
  • Dapagliflozin Isomer Impurity
  • Dapagliflozin, >=98%
  • apagliflozin
  • Farxiga
  • Dapagliflozin USP/EP/BP
  • Dagagflozin
  • Dagliejing
  • Dapagli ozin
  • Dapagliflozen amorphous
  • High Quality Dapagliflozin CAS No. 461432-26-8 with Safe Shipping
  • (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hy...
  • DapagliflozinQ: What is Dapagliflozin Q: What is the CAS Number of Dapagliflozin Q: What is the storage condition of Dapagliflozin Q: What are the applications of Dapagliflozin
  • Glenn net
  • DAPAGLIFLOZIN（base，Amorphous）
  • (1S)-1,5- dehydration -1-C-[4- chloro -3-[(4- ethoxyphenyl) methyl] phenyl ]-D- glucitol
  • BMS512148,Sodium-dependent glucose cotransporters,SGLT,BMS 512148,inhibit,Dapagliflozin,Inhibitor
  • (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
  • Dapagliflozin CRS
  • Dagliflozin
  • 2-Chloro-5-（ β- D-glucopyrano-1-yl) -4 '- ethoxydiphenylmethane
  • Dapagliflozin (Propanediol Monohydrate & Amorphous)
  • Dapgliflozin
  • Dapagliflozin Reference Standard
  • 461432-26-8
  • 61432-26-8
  • 46132-26-8
  • 461432-26-8;960404-48-2
  • 461436-26-8
  • C21H25ClO6
  • Inhibitors
  • Other APIs
  • APIs
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • 461432-26-8